GT Biopharma
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -2,848 | -5,595 | -3,382 | -1,513 |
Net Income | -2,833 | -23,031 | 8,299 | -30,169 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -2,468 | -4,021 | -3,677 | -3,014 |
Cash | 8,923 | 6,811 | 2,621 | 5,228 |
Basic Shares | 30,283 | 5,513 | 3,940 | 2,771 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -12,422 | -13,162 | 5,979 | -20,965 |
EBIT | -27,526 | -7,597 | -42,222 | |
Net Income | -28,354 | -13,162 | -7,597 | -20,884 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -12,914 | -12,904 | -8,852 | -15,217 |
Cash | 6,811 | 3,951 | 1,079 | 5,672 |
Basic Shares | 5,513 | 1,897 | 1,348 | 31,868 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.11 |
2025-12-31 | -$4.84 |
2025-09-30 | -$0.83 |
2025-06-30 | -$0.55 |